Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-14
2011-06-14
Lundgren, Jeffrey S. (Department: 1613)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S400000
Reexamination Certificate
active
07960350
ABSTRACT:
Embodiments of the invention disclosed herein relate to methods of preventing and/or ameliorating one or more symptoms associated with an eye disease such as dry eye syndrome, cataracts of the eye and nuclear sclerosis of the eye lens by administering to a subject a therapeutically effective amount of Nα-acetyl-L-histidine. Additionally, provided herein are pharmaceutical compositions comprising Nα-acetyl-L-histidine. Kits for preventing and/or ameliorating one or more symptoms associated with an eye disease by administering a pharmaceutical composition comprising Nα-acetyl-L-histidine are also disclosed.
REFERENCES:
patent: 4426330 (1984-01-01), Sears
patent: 4534899 (1985-08-01), Sears
patent: 4837028 (1989-06-01), Allen
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5225212 (1993-07-01), Martin et al.
patent: 5356633 (1994-10-01), Woodle et al.
patent: 5512592 (1996-04-01), Zaloga et al.
patent: 5540935 (1996-07-01), Miyazaki et al.
patent: 5543152 (1996-08-01), Webb et al.
patent: 5556948 (1996-09-01), Tagawa et al.
patent: 5705188 (1998-01-01), Junichi et al.
patent: 5795912 (1998-08-01), Tsubota
patent: 5811446 (1998-09-01), Thomas
patent: 6159485 (2000-12-01), Yu et al.
patent: 6281192 (2001-08-01), Leahy et al.
patent: 6629970 (2003-10-01), Bagrov et al.
patent: 445131 (1994-04-01), None
patent: 496813 (1994-12-01), None
patent: 666753 (2000-11-01), None
patent: WO8804924 (1988-07-01), None
patent: WO9004384 (1990-05-01), None
patent: WO9105545 (1991-05-01), None
patent: WO9420073 (1994-09-01), None
patent: WO9510294 (1995-04-01), None
patent: WO9610391 (1996-04-01), None
patent: WO9713499 (1997-04-01), None
Morris Baslow, Function of the N-Acetyl-L-Histidine System in the Vertebrate Eye, 10 J. Mol. Neurosci. 193 (1998).
Shulin Ding, Recent Developments in Ophthalmic Drug Delivery, 1 PSTT 328 (Nov. 1998).
MayoClinic.com, Cataracts Symptoms, available at http://www.mayoclinic.com/health/cataracts/DS00050/DSECTION=symptoms.
Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics, U.S. Department of Health and Human Services, Food and Drug Administration, May 1999.
Leo Chylack, et al, Classification of Human Senile Cataractous Change by the American Cooperative Cataract Research Group (CCRG) Method, 25 Inv. Ophthalmol. Vis. Sci. 174, (1984).
Mark Babizhayev, Antioxidant Activity of L-Carnosine, a Natural Histidine-Containing Dipeptide in Crystalline Lens, 1004 Biochim. Biophysica Acta 363 (1989).
International Search Report from PCT/US04/35021 dated Oct. 11, 2005.
Written Opinion of the International Searching Authority from PCT/US04/35021 dated Oct. 11, 2005.
Babizhayev, 1989Biochemica et Biophysica Acta1004:363-371.
Babizhayev, 1996Clinica Chimica Acta254:1-21.
Biros, et al. 2000.J. Am. Vet. Med. Assoc.216:1780-6.
Statistics on Vision Impairment: A Resource Manual, 5thedition, Apr. 2002.
Mican, Phil, “An interview with Mark Babizhayev Ph.D. about the development of NAC eye-drops” obtained from: http://www.antiaging-systems.com/ARTICLE-490/babizhayev-can-c-development.htm, on Oct. 18, 2010.
“Eye Medications” obtained from: http://www.uic.edu/com/eye/LearningAboutVision/EyeFacts/MedicineForEyes.shtml, on Oct. 18, 2010, dated Jan. 1, 1992.
ADER Enterprises, Inc.
Basquill Sean
Knobbe Martens Olson & Bear LLP
Lundgren Jeffrey S.
LandOfFree
Composition and method for the treatment of eye disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for the treatment of eye disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for the treatment of eye disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2740761